MedTrace Logo

Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease

NCT03111485 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-03-13

No results posted yet for this study

Summary

This trial will assess whether long-acting levodopa taken at night improves obstructive sleep apnea (OSA) in patients with Parkinson's disease (PD), as compared with placebo.

Conditions

Interventions

DRUG

Sinemet CR

Capsule 250 mg / 50 mg taken at bedtime

DRUG

Placebo oral capsule

Capsule taken at bedtime

Sponsors & Collaborators

  • Weston Brain Institute

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Marta Kaminska, MD, MSc · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111485 on ClinicalTrials.gov